Company intelligence / Profile preview

Reapplix

Birkerød, Capital Region of Denmark, Denmarkreapplix.com ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

Reapplix has developed the evidence-based, autologous biological wound therapy system called the 3C Patch®, which uses only a patient’s own blood to create a patch applied directly to chronic wounds such as diabetic foot ulcers. The company’s technology has demonstrated positive results in large randomized controlled trials and received coding/reimbursement approval in the US. The company is currently commercializing its product in the US and select European markets.

Therapeutic areas: EndocrinologyDermatology
Modalities: DeviceBiologic (autologous blood-derived patch)Regenerative medicine therapy
Industry: Biotech

Drug pipeline

1 asset

3C Patch

Commercial

Indications: Diabetic foot ulcers

Beyond the preview

Go deeper on Reapplix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reapplix.

Explore the full profile